Contraceptive Market by Product (Devices, Drugs), Gender (Female Contraceptive, Male Contraceptive), Method, Distribution - Global Forecast 2024-2030
The Contraceptive Market size was estimated at USD 48.43 billion in 2023 and expected to reach USD 54.87 billion in 2024, at a CAGR 13.82% to reach USD 119.89 billion by 2030.
Contraceptives, also known as birth control, are methods or devices used to prevent pregnancy. These products or practices can work in various ways, such as inhibiting the fertilization of an egg, preventing the implantation of a fertilized egg in the uterus, or regulating hormonal cycles. The availability and choice of contraception provide individuals with the ability to plan if and when they want to have children, contributing to better health outcomes for women and families. Increased educational campaigns and government initiatives to raise awareness about sexual health and contraceptives have increased the adoption of various contraceptive methods. Further, enhanced access to healthcare services and family planning in emerging economies has increased the use of contraceptives. Innovations in contraceptive methods leading to more efficient and user-friendly options also bolstered the market growth. However, strict regulatory frameworks can delay product approvals and launches. Resistance in certain regions due to traditional beliefs and religious constraints may pose challenges for the market. Nevertheless, investigating biodegradable and eco-friendly contraceptive products to cater to environmentally conscious consumers is expected to provide an opportunistic way for market growth. Moreover, developments in male contraception methods may bolster the market growth shortly.
Regional Insights
The contraceptive market in the Americas presents a mature landscape with high awareness levels and a strong presence of major pharmaceutical companies. The region is characterized by a wide range of contraceptive methods including birth control pills, IUDs, implants, and condoms. Government policies and non-profit organizations in the United States and Canada play a crucial role in providing accessible contraception, particularly to younger and lower-income populations. The Latin American market is experiencing growth, propelled by public health initiatives aimed at reducing teenage pregnancies and increasing the availability of contraceptives. The EMEA region presents a varying landscape for contraceptives. Europe has a well-established market with high contraceptive prevalence rates, backed by governmental healthcare systems that offer various contraceptive methods at low or no cost. There is a strong tendency toward long-acting reversible contraceptives (LARCs) such as IUDs. The Middle East, contrastingly, has cultural and religious factors that influence contraceptive use, with varying degrees of accessibility and societal acceptance across different countries. The African continent shows the lowest contraceptive prevalence rate and is experiencing a rise in need for family planning services, driven by international aid, and increasing government focus on women's health issues. The Asia-Pacific region showcases a diverse contraceptive market, heavily influenced by cultural, social, and regulatory factors. The presence of high-population countries coupled with government initiatives and awareness campaigns for the use of contraceptives has propelled the market growth in the region.
Market Insights
Market Dynamics
The market dynamics represent an ever-changing landscape of the Contraceptive Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
Market Drivers
Increased awareness regarding sexual health and family planning
Supportive government initiatives to encourage use and provision of contraceptive pills
Market Restraints
Adverse health impacts of contraceptive products
Market Opportunities
Introduction of affordable contraceptive methods with extensive R&D
Availability of contraceptives through online distribution channels
Market Challenges
Social concerns regarding contraceptive usage and issues with product marketing
Market Segmentation Analysis
Product: High inclination toward contraceptive drugs due to their ease of use and non-invasiveness
Gender: Significant adoption of female contraceptives due to availability of a wide range of products
Method: Rising preference for barrier methods of contraception that provide a physical and chemical barrier during sexual activities
Distribution Channel: Enhanced product distribution through online pharmacies due to their 24/7 services
Market Disruption Analysis
Porter’s Five Forces Analysis
Value Chain & Critical Path Analysis
Pricing Analysis
Technology Analysis
Patent Analysis
Trade Analysis
Regulatory Framework Analysis
FPNV Positioning Matrix
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Contraceptive Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Contraceptive Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments
Richmond Biotech Company to buy Contraceptive biz for USD 100 Million
Aditxt has announced its intent to acquire Evofem Biosciences, a contraceptive business located in California, for a total purchase price of USD 100 million. The agreement, which has received unanimous approval from the boards of both companies, is slated for completion in the initial half of this year. Evofem Biosciences is known for its innovative product, Phexxi, a non-hormonal contraceptive gel, and the acquisition is expected to incorporate Evofem as a wholly owned subsidiary of Aditxt, further solidifying Aditxt's position in the healthcare market while broadening its product offerings.
UK Launches First Trial of Hormone-free Male Birth Control pill
UK-based Quotient Sciences has initiated the initial trials for YCT-529, an innovative non-hormonal male contraceptive pill. This landmark study, involving 16 participants, is expected to redefine birth control by offering men a hormone-free option. As the goal of gender-inclusive contraceptive methods intensifies, YCT-529 signifies a progressive stride toward balancing the responsibilities of family planning. Quotient Sciences' commitment to this novel approach could not only transform the marketplace for contraceptives but also catalyze a shift in societal norms surrounding reproductive health.
Aditxt Acquires Phexxi Contraceptive Gel-Maker Evofem for USD 100 million
US-based biotech firm Aditxt has announced the acquisition of Evofem Biosciences in a strategic deal valued at approximately USD 100 million. This acquisition represents a significant step for Aditxt, marking its entrance into the sexual and reproductive health sector. This move is anticipated to broaden Aditxt's product range and reinforce its position in the market by catering to the diverse needs of consumers seeking non-hormonal contraceptive methods.
Strategy Analysis & Recommendation
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Contraceptive Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the Contraceptive Market, highlighting leading vendors and their innovative profiles. These include Abbvie Inc., Acme Generics Pvt. Ltd., Afaxys, Inc., Agile Therapeutics, Inc., Amneal Pharmaceuticals LLC, ASKA Pharmaceutical Co., Ltd., Aurobindo Pharma Limited, Bayer AG, Church & Dwight Co., Inc., HLL Lifecare Limited, Insud Pharma, S.L., Johnson & Johnson Services, Inc., Lupin Limited, Mayne Pharma Group Limited, Merck & Co., Inc., Mithra Pharmaceuticals S.A., Okamoto Industries, Inc., Organon & Co., Perrigo Company plc, Pfizer Inc., Piramal Pharma Ltd., Reckitt Benckiser Group plc, RITEX GMBH, Sanofi S.A., Say It With A Condom, LLC., Syzygy Healthcare Solutions LLC, Teva Pharmaceutical Industries Ltd., TherapeuticsMD, Inc., TTK Healthcare Limited, Veru Inc., and Viatris Inc..
Market Segmentation & Coverage
This research report categorizes the Contraceptive Market to forecast the revenues and analyze trends in each of the following sub-markets:
Product
Devices
Condoms
Diaphragm
IUDs
Copper IUDs
Hormonal IUDs
Subdermal Implants
Vaginal Rings
Drugs
Injectables
Oral Contraceptive Pills
Transdermal Contraceptive Patch
Gender
Female Contraceptive
Male Contraceptive
Method
Barrier
Harmonal
Distribution
Chain Pharmacy
Clinics
Government Network
Hospital Pharmacy
Independent Pharmacy
Online Platform
Region
Americas
Argentina
Brazil
Canada
Mexico
United States
California
Florida
Illinois
New York
Ohio
Pennsylvania
Texas
Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam
Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom
Please Note: PDF & Excel + Online Access - 1 Year
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increased awareness regarding sexual health and family planning
5.1.1.2. Supportive government initiatives to encourage use and provision of contraceptive pills
5.1.2. Restraints
5.1.2.1. Adverse health impacts of contraceptive products
5.1.3. Opportunities
5.1.3.1. Introduction of affordable contraceptive methods with extensive R&D
5.1.3.2. Availability of contraceptives through online distribution channels
5.1.4. Challenges
5.1.4.1. Social concerns regarding contraceptive usage and issues with product marketing
5.2. Market Segmentation Analysis
5.2.1. Product: High inclination toward contraceptive drugs due to their ease of use and non-invasiveness
5.2.2. Gender: Significant adoption of female contraceptives due to availability of a wide range of products
5.2.3. Method: Rising preference for barrier methods of contraception that provide a physical and chemical barrier during sexual activities
5.2.4. Distribution Channel: Enhanced product distribution through online pharmacies due to their 24/7 services
5.3. Market Trend Analysis
5.3.1. Significant advancements in contraceptive methods coupled with increasing government and non-government initiatives to promote contraceptives across the Americas
5.3.2. Strong government support to spread awareness of contraceptives and extensive R&D activities to expand product profiles in APAC
5.3.3. Increasing government initiatives promoting family planning and sexual health education, with ongoing advancements in contraceptive methods across EMEA
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework Analysis
6. Contraceptive Market, by Product
6.1. Introduction
6.2. Devices
6.3. Drugs
7. Contraceptive Market, by Gender
7.1. Introduction
7.2. Female Contraceptive
7.3. Male Contraceptive
8. Contraceptive Market, by Method
8.1. Introduction
8.2. Barrier
8.3. Harmonal
9. Contraceptive Market, by Distribution
9.1. Introduction
9.2. Chain Pharmacy
9.3. Clinics
9.4. Government Network
9.5. Hospital Pharmacy
9.6. Independent Pharmacy
9.7. Online Platform
10. Americas Contraceptive Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Contraceptive Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Contraceptive Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
13.3.1. Richmond Biotech Company to buy Contraceptive biz for USD 100 Million
13.3.2. UK Launches First Trial of Hormone-free Male Birth Control pill
13.3.3. Aditxt Acquires Phexxi Contraceptive Gel-Maker Evofem for USD 100 million
13.3.4. Daré Bioscience Launches Phase III Hormone-free Contraceptive Trial
13.3.5. Lupin Launches Turqoz (Norgestrel and Ethinyl Estradiol) Tablets USP in the United States
13.3.6. Bayer and CrossBay Medical to Develop Novel Intrauterine System Inserter
13.3.7. Xiromed LLC Announces Launch of EnilloRing in the United States
13.3.8. Bayer Invests in USD 267.2 Million new Production Facility in Finland to Accelerate Global Access to Modern Contraception
13.3.9. NIH Center Grant Bolsters Male Contraceptive Research
13.3.10. Gates Foundation, Children’s Investment Fund Foundation, Pfizer and BD Company Expand Partnership for Greater Access to Injectable Contraceptive for Women
13.3.11. Perrigo Announces U.S. FDA Approval for Opill OTC Daily Oral Contraceptive
13.3.12. FDA Approves First Nonprescription Daily Oral Contraceptive
13.3.13. Sirona Acquires India’s First Vegan Condom Brand Bleu